CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo

Journal of Immunology

Volumn 181, Issue 11, 2009, Pages 8088-8095

  Dormond, Olivier ^a   Contreras, Alan G ^c   Meijer, Esther ^c   Datta, Dipak ^c   Flynn, Evelyn ^c   Pal, Soumitro ^c   Briscoe, David M ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; INITIATION FACTOR 4E BINDING PROTEIN 1; LUCIFERASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; MAMMALIAN TARGET OF RAPAMYCIN C2; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; S6 KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBROBLAST; GENE ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 71849091933     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.11.8088     Document Type: Article

References (42)

1. Schonbeck, U., and P. Libby. 2001. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58: 4-43.
2. Grewal, I. S., and R. A. Flavell. 1997. The CD40 ligand: at the center of the immune universe? Immunol. Res. 16: 59-70. (Pubitemid 27129629)
3. van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378: 620-623.
4. Henn, V., J. R. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster, G. Muller-Berghaus, and R. A. Kroczek. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594. (Pubitemid 28157601)
5. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr., and R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273: 1864-1867.
6. Stout, R. D., J. Suttles, J. Xu, I. S. Grewal, and R. A. Flavell. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156: 8-11.
7. Buhlmann, J. E., T. M. Foy, A. Aruffo, K. M. Crassi, J. A. Ledbetter, W. R. Green, J. C. Xu, L. D. Shultz, D. Roopesian, R. A. Flavell, et al. 1995. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 2: 645-653.
8. Xu, J., T. M. Foy, J. D. Laman, E. A. Elliott, J. J. Dunn, T. J. Waldschmidt, J. Elsemore, R. J. Noelle, and R. A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity 1: 423-431.
9. Grewal, I. S., J. Xu, and R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378: 617-620.
10. + CTL response. J. Exp. Med. 183: 2129-2142.
11. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, M. Neubauer, et al. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper- IgM syndrome. Cell 72: 291-300. (Pubitemid 23044943)
12. Melter, M., M. E. Reinders, M. Sho, S. Pal, C. Geehan, M. D. Denton, D. Mukhopadhyay, and D. M. Briscoe. 2000. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96: 3801-3808.
13. Reinders, M. E., M. Sho, S. W. Robertson, C. S. Geehan, and D. M. Briscoe. 2003. Proangiogenic function of CD40 ligand-CD40 interactions. J. Immunol. 171: 1534-1541.
14. Chiodoni, C., M. Iezzi, C. Guiducci, S. Sangaletti, I. Alessandrini, C. Ratti, F. Tiboni, P. Musiani, D. N. Granger, and M. P. Colombo. 2006. Triggering CD40 on endothelial cells contributes to tumor growth. J. Exp. Med. 203: 2441-2450. (Pubitemid 44664614)
15. Bergmann, S., and P. P. Pandolfi. 2006. Giving blood: a new role for CD40 in tumorigenesis. J. Exp. Med. 203: 2409-2412. (Pubitemid 44664609)
16. Flaxenburg, J. A., M. Melter, P. H. Lapchak, D. M. Briscoe, and S. Pal. 2004. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J. Immunol. 172: 7503-7509.
17. Lapchak, P. H., M. Melter, S. Pal, J. A. Flaxenburg, C. Geehan, M. H. Frank, D. Mukhopadhyay, and D. M. Briscoe. 2004. CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am. J. Physiol. 287: F512-F520.
18. Deregibus, M. C., S. Buttiglieri, S. Russo, B. Bussolati, and G. Camussi. 2003. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J. Biol. Chem. 278: 18008-18014. (Pubitemid 36799410)
19. Phung, T. L., K. Ziv, D. Dabydeen, G. Eyiah-Mensah, M. Riveros, C. Perruzzi, J. Sun, R. A. Monahan-Earley, I. Shiojima, J. A. Nagy, et al. 2006. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10: 159-170.
20. Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
21. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
22. Pearce, L. R., X. Huang, J. Boudeau, R. Pawlowski, S. Wullschleger, M. Deak, A. F. Ibrahim, R. Gourlay, M. A. Magnuson, and D. R. Alessi. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405: 513-522.
23. Woo, S. Y., D. H. Kim, C. B. Jun, Y. M. Kim, E. V. Haar, S. I. Lee, J. W. Hegg, S. Bandhakavi, and T. J. Griffin. 2007. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor β expression and signaling. J. Biol. Chem. 282: 25604-25612.
24. Dormond, O., J. C. Madsen, and D. M. Briscoe. 2007. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282: 23679-23686. (Pubitemid 47311969)
25. Boulday, G., Z. Haskova, M. E. Reinders, S. Pal, and D. M. Briscoe. 2006. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-γ-inducible protein of 10 kDa in vitro and in vivo. J. Immunol. 176: 3098-3107. (Pubitemid 43306972)
26. Moulton, K. S., R. J. Melder, V. R. Dharnidharka, J. Hardin-Young, R. K. Jain, and D. M. Briscoe. 1999. Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation 67: 1626-1631. (Pubitemid 29315688)
27. Fingar, D. C., S. Salama, C. Tsou, E. Harlow, and J. Blenis. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/ eIF4E. Genes Dev. 16: 1472-1487.
28. Hudson, C. C., M. Liu, G. G. Chiang, D. M. Otterness, D. C. Loomis, F. Kaper, A. J. Giaccia, and R. T. Abraham. 2002. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22: 7004-7014.
29. Land, S. C., and A. R. Tee. 2007. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 282: 20534-20543.
30. Briscoe, D. M., V. R. Dharnidharka, C. Isaacs, G. Downing, S. Prosky, P. Shaw, N. L. Parenteau, and J. Hardin-Young. 1999. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation 67: 1590-1599.
31. Phung, T. L., G. Eyiah-Mensah, R. K. O'Donnell, R. Bieniek, S. Shechter, K. Walsh, C. Kuperwasser, and L. E. Benjamin. 2007. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res. 67: 5070-5075.
32. Durie, F. H., R. A. Fava, T. M. Foy, A. Aruffo, J. A. Ledbetter, and R. J. Noelle. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261: 1328-1330. (Pubitemid 24081170)
33. Danese, S., F. Scaldaferri, S. Vetrano, T. Stefanelli, C. Graziani, A. Repici, R. Ricci, G. Straface, A. Sgambato, A. Malesci, et al. 2007. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 56: 1248-1256. (Pubitemid 47300427)
34. Reul, R. M., J. C. Fang, M. D. Denton, C. Geehan, C. Long, R. N. Mitchell, P. Ganz, and D. M. Briscoe. 1997. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 64: 1765-1774.
35. Reinders, M. E., J. C. Fang, W. Wong, P. Ganz, and D. M. Briscoe. 2003. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76: 224-230. (Pubitemid 36877141)
36. Lemstrom, K. B., R. Krebs, A. I. Nykanen, J. M. Tikkanen, R. K. Sihvola, E. M. Aaltola, P. J. Hayry, J. Wood, K. Alitalo, S. Yla-Herttuala, and P. K. Koskinen. 2002. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105: 2524-2530. (Pubitemid 34568975)
37. Kanazawa, S., T. Tsunoda, E. Onuma, T. Majima, M. Kagiyama, and K. Kikuchi. 2001 Mar. VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96: 822-828. (Pubitemid 32240738)
38. Hoshino, M., M. Takahashi, and N. Aoike. 2001. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 107: 295-301. (Pubitemid 32173907)
39. Ferrara, N. 2005. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94: 209-231.
40. Sone, H., Y. Kawakami, M. Sakauchi, Y. Nakamura, A. Takahashi, H. Shimano, Y. Okuda, T. Segawa, H. Suzuki, and N. Yamada. 2001. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. 281: 562-568. (Pubitemid 32928191)
41. Miotla, J., R. Maciewicz, J. Kendrew, M. Feldmann, and E. Paleolog. 2000. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. 80: 1195-1205. (Pubitemid 30637059)
42. Oliver, S. J., T. P. Cheng, M. L. Banquerigo, and E. Brahn. 1995. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell. Immunol. 166: 196-206.